ScinoPharm Taiwan (1789) Q1 2026 EPS: NT$0.02
Key facts
- ScinoPharm Taiwan (1789) Q1 2026 EPS: NT$0.02
- ScinoPharm Taiwan announced its Q1 2026 financial results, with consolidated EPS of NT$0.02, operating revenue of NT$660 million, and after-tax net profit of NT$17 million. This reflects the latest financial status of the company in the biotechnology and healthcare industry.
- Source: PR Times
- Date: March 1, 2026
Direct answer
ScinoPharm Taiwan announced its Q1 2026 financial results, with consolidated EPS of NT$0.02, operating revenue of NT$660 million, and after-tax net profit of NT$17 million. This reflects the latest financial status of the company in the biotechnology and healthcare industry.
- Citation
- ScinoPharm Taiwan (1789) Q1 2026 EPS: NT$0.02 (March 1, 2026), PR Times
- Source
- PR Times
- Date
- March 1, 2026
ScinoPharm Taiwan announced its Q1 2026 financial results, with consolidated EPS of NT$0.02, operating revenue of NT$660 million, and after-tax net profit of NT$17 million. This reflects the latest financial status of the company in the biotechnology and healthcare industry.
📋 Article Processing Timeline
- 📰 Published: March 1, 2026 at 09:00
- 🔍 Collected: May 7, 2026 at 08:00 (1607h 0m after Published)
- 🤖 AI Analyzed: May 7, 2026 at 08:04 (3 min after Collected)
Company Name: ScinoPharm Taiwan, Ltd.
Industry: Biotechnology and Healthcare Industry
Period: Q1 2026
Basic Earnings Per Share: NT$0.02
Operating Revenue: NT$660 million
After-tax Net Profit: NT$17 million
FAQ
What are the key facts in this article?
ScinoPharm Taiwan announced its Q1 2026 financial results, with consolidated EPS of NT$0.02, operating revenue of NT$660 million, and after-tax net profit of NT$17 million. This reflects the latest financial status of the company in the biotechnology and healthcare industry.
What is the direct answer?
ScinoPharm Taiwan announced its Q1 2026 financial results, with consolidated EPS of NT$0.02, operating revenue of NT$660 million, and after-tax net profit of NT$17 million. This reflects the latest financial status of the company in the biotechnology and healthcare industry.
What is the source and date?
PR Times: https://openapi.twse.com.tw/financial/twse-fin-1789-2026Q1 | March 1, 2026